Abstract
Unresectable advanced hepatocellular carcinoma is a heterogeneous disease, for which sorafenib is the first targeted agent approved for first-line therapy, and treatment options for patients with sorafenib-refractory advanced hepatocellular carcinoma are limited. We assessed the efficacy and safety of S-1, a chemotherapeutic agent based on fluorouracil, in patients with sorafenib-refractory advanced hepatocellular carcinoma. We did a randomised, double-blind, placebo-controlled, phase 3 study done at 57 sites in Japan. Patients with advanced hepatocellular carcinoma who were ineligible for surgical or local-regional therapy and judged refractory to sorafenib (ie, had progressed on sorafenib or had discontinued sorafenib because of adverse events) were randomly assigned (2:1) to receive oral S-1 (weight-banded 80 mg/m2 [80-120 mg per day]), or placebo, twice per day for 28 days consecutively, followed by a minimum 14 day drug-free period. This cycle was repeated until disease progression or the patient became intolerant to the study treatment. Patients were stratified by site and presence or absence of extrahepatic metastasis or vascular invasion. The primary endpoint was overall survival, assessed in the full analysis set (ie, ...Continue Reading
Citations
Dec 19, 2017·Japanese Journal of Clinical Oncology·Masafumi IkedaJunji Furuse
Jan 30, 2018·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Hiroaki NaganoMorito Monden
Sep 12, 2017·Investigational New Drugs·Sadahisa OgasawaraNaoya Kato
Jun 19, 2018·Expert Opinion on Pharmacotherapy·Shun Yamamoto, Shunsuke Kondo
Dec 24, 2018·Journal of Clinical Gastroenterology·Ziad BakounyFadi Nasr
Jun 18, 2019·Future Oncology·Nicola PersoneniLorenza Rimassa
Oct 23, 2018·Oncotarget·Yoshinobu ShigekawaHiroki Yamaue
May 21, 2020·Liver International : Official Journal of the International Association for the Study of the Liver·Lorenza Rimassa, Marcus-Alexander Wörns
Nov 2, 2018·Cancers·Masatoshi Kudo
Jun 12, 2018·Liver Cancer·Masatoshi Kudo
May 1, 2020·Cancers·Masatoshi Kudo
Jul 25, 2018·Alimentary Pharmacology & Therapeutics·Matthias Pinter, Markus Peck-Radosavljevic
Feb 28, 2019·World Journal of Gastroenterology : WJG·Masatoshi Kudo
Oct 28, 2019·Journal of Hematology & Oncology·Xiao-Dong Zhu, Hui-Chuan Sun
Jun 7, 2019·Investigational New Drugs·Sadahisa OgasawaraNaoya Kato
Jan 20, 2021·Medicina clínica·María ReigJordi Bruix
Dec 11, 2020·Critical Reviews in Oncology/hematology·Maciej GryziakRafał Stec
Mar 17, 2021·Expert Opinion on Emerging Drugs·Landon L Chan, Stephen L Chan
Oct 6, 2018·Gastroenterology·Tim F GretenKevin F Staveley-O'Carroll
May 13, 2021·Clinical Journal of Gastroenterology·Satoko MotegiShuji Terai
Jun 20, 2021·Clinical and Experimental Medicine·Antonio Giovanni SolimandoVito Racanelli
Jul 15, 2021·Japanese Journal of Clinical Oncology·Junji FuruseMasafumi Ikeda
Jun 15, 2021·Gastroenterology·Philipp K HaberJosep M Llovet
Jul 3, 2021·The Kaohsiung Journal of Medical Sciences·Tsung-Che WuAnn-Lii Cheng
Aug 14, 2021·Translational Oncology·Hiroyuki SuzukiTakuji Torimura
Sep 25, 2021·Medicine·Jianxin ChenFangwei Xie
Nov 27, 2019·Liver Cancer·Mohamed BouattourJean-Charles Nault
Dec 5, 2019·Liver Cancer·Lorenza RimassaPhilippe Merle
Oct 2, 2020·Liver Cancer·Masatoshi Kudo
Oct 2, 2020·Liver Cancer·Susumu MarutaNaoya Kato
Oct 12, 2019·Liver Cancer·Masatoshi Kudo
Nov 16, 2021·Liver International : Official Journal of the International Association for the Study of the Liver·Sadahisa OgasawaraNaoya Kato